REG - Futura Medical PLC - Exercise of Warrants

Futura MedicalAnnouncement

12/06/2023 08:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230612:nRSL3898Ca&default-theme=true

RNS Number : 3898C  Futura Medical PLC  12 June 2023

12 June 2023

Futura Medical plc

("Futura" or the "Company")

Exercise of Warrants, Issue of Equity and Total Voting Rights

Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio
of innovative products based on its proprietary, transdermal DermaSys® drug
delivery technology and currently focused on sexual health and pain, announces
that it has today received a warrant exercise notice (the "Notice") from
Lombard Odier Asset Management (Europe) Limited ("Lombard Odier") in respect
of 10,937,500 ordinary shares of 0.2 pence in the Company ("Ordinary Shares"),
with an exercise price of 40 pence per share. The Notice is in respect of all
warrants previously held by Lombard Odier. Proceeds of £4,375,000 will be
 received by the Company in respect of the warrant exercise.

Application will be made for the 10,937,500 Ordinary Shares to be admitted to
trading on AIM ("Admission") and it is expected that Admission will occur on
or around 16 June 2023.

Total voting rights

Following Admission, the Company's enlarged issued share capital will comprise
299,071,457 Ordinary Shares, with one voting right per share. The Company does
not hold any Ordinary Shares in treasury and therefore the total number of
Ordinary Shares with voting rights in the Company is 299,071,457.

The above figure of 299,071,457 may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the share capital
of the Company under the FCA's Disclosure Guidance and Transparency Rules.

James Barder, Futura's Chief Executive Officer, commented: "Support from all
our shareholders provides the company with continued cash security from which
to grow and look to the future with confidence. I welcome today's announcement
and the support from Lombard Odier, as these funds provide Futura Medical with
good visibility into 2025 as the Company prepares for the next chapter of
growth with anticipated launches, and the scale up of commercialisation of
MED3000".

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit)
Regulations 2019. Upon the publication of this announcement via the Regulatory
Information Service, this inside information is now considered to be in the
public domain.

-ENDS-

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com

Tel: +44 (0) 1483 685 670

www.futuramedical.com (http://www.futuramedical.com/)

Nominated Adviser and Sole Broker:

Liberum

Phil Walker/ Richard Lindley/ Ben Cryer

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Hollie Vile/ Jonathan Edwards/ Zoe Bolt

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 882 9621

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPUGPQUPWUMP